ClinicalTrials.gg

Program

lofexidine

Also written as “Lofexidine HCl”, “Lofexidine” and “Lofexidine hydrochloride”.

Its studies are mostly in Opioid-Related Disorders · Liver Failure · Kidney Failure, Chronic, led by USWM, LLC (dba US WorldMeds).

Furthest: phase 3, since May 22, 201315 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
USWM, LLC (dba US WorldMeds)150 open or runningphase 3since May 22, 2013Mar 4, 2011none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 4, 2011.

  1. Sep 13, 2011Phase 1 study in HealthyNCT01437306 · 13 enrolled · United States
  2. Feb 14, 2012Phase 1 study in Opioid-Related DisordersNCT01558934 · 6 enrolled · United States
  3. Jun 14, 2012Phase 1 study in Normal Healthy VolunteersNCT01629446 · 6 enrolled · United States
  4. Jul 9, 2012Phase 1 study in Opioid-Related DisordersNCT01650649 · 27 enrolled · United States
  5. Mar 25, 2013Phase 1 study in Opioid-Related DisordersNCT01820442 · 30 enrolled · United States
  6. May 22, 2013Phase 3 study in Opioid-Related DisordersNCT01863186 · 603 enrolled · United States
  7. Jul 29, 2014Phase 1 study in Liver FailureNCT02318836 · 24 enrolled · United States
  8. Dec 5, 2014Phase 1 study in Kidney Failure, ChronicNCT02313103 · 16 enrolled · United States
  9. Feb 9, 2015Phase 3 study in Opioid WithdrawalNCT02363998 · 286 enrolled · United States
  10. May 7, 2015Phase 1 study in HealthyNCT02446002 · 25 enrolled · United States
  11. Feb 1, 2016Phase 1 study in HealthyNCT02681198 · 24 enrolled · United States
  12. Jul 2, 2019Phase 2 study in Opioid Withdrawal (Disorder)NCT04070157 · 4 enrolled · United States
  13. Nov 25, 2019Phase 1 study in Normal Healthy VolunteersNCT04188730 · 16 enrolled · United States
  14. Nov 19, 2024Phase 1 study in Opioid-Related DisordersNCT06711640 · United States

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brimonidineruleAbbViephase 454
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
Clonidinerulepharmafinaphase 45

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06711640Opioid-Related Disorders · United States1WithdrawnJan 20260
NCT04188730Normal Healthy Volunteers · United States1CompletedMar 26, 202116
NCT04070157Opioid Withdrawal (Disorder) · United States2TerminatedNov 27, 20194
NCT02681198Healthy · United States1CompletedMar 201624
NCT02446002Healthy · United States1CompletedJun 201525
NCT02363998Opioid Withdrawal · United States3CompletedSep 2015286
NCT02313103Kidney Failure, Chronic · United States1CompletedFeb 201516
NCT02318836Liver Failure · United States1CompletedOct 201424
NCT01863186Opioid-Related Disorders · United States3CompletedNov 2014603
NCT01820442Opioid-Related Disorders · United States1CompletedSep 201330
NCT01650649Opioid-Related Disorders · United States1CompletedDec 201227
NCT01629446Normal Healthy Volunteers · United States1CompletedJun 20126
NCT01558934Opioid-Related Disorders · United States1CompletedApr 20126
NCT01437306Healthy · United States1CompletedOct 201113
NCT01310296Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product · United States1CompletedAug 201112

How it is read

Names in the registry

  • “Lofexidine HCl”, 5 entries
  • “Lofexidine”, 3 entries
  • “Lofexidine hydrochloride”, 3 entries
  • “LUCEMYRA (lofexidine) tablets”, 1 entry
  • “Lofexidine (granules for reconstitution)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.